Pacific Edge Limited (PFGTF) has released an update.
Pacific Edge Limited, a cancer diagnostics company, reported a slight increase in test volumes for its Cxbladder product in Q4 24, despite a reduction in their sales force. The company saw a 0.4% increase in tests processed, reaching 7,210 tests, and a 30.4% increase in sales force efficiency. This performance is attributed to sales improvements, strategic partnerships, and consistent demand from physicians, while overall annual growth was tempered by uncertainties in Medicare coverage.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
